1. Generics Bulletin
  2. >>Business

Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios

Latest Acquisition Should See Firm’s Annual Gross Sales Expand To €600m

 
• By Chloe Kent

CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.

Graphic depiction of central nervous system
Neuraxpharm has purchased two portfolios of CNS, pain and vascular disease products • Source: Shutterstock

Privately-owned central nervous system specialist Neuraxpharm has struck a deal with Sanofi to acquire two product portfolios for CNS, pain and vascular diseases, a move which it expects will lead to its annual gross sales hitting around €600m ($603m) and will significantly expand its portfolio of branded products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab

 
• By Dave Wallace

Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.